Get to know our clinical trials

Clinical trial of erenumab in subjects with high-frequency episodic migraine.

THIS STUDY IS BEING CONDUCTED TO OBTAIN MORE INFORMATION ON THE BENEFIT OF ERENUMAB TREATMENT, APART FROM THE EFFECT ON THE NUMBER OF MIGRAINE DAYS PER MONTH. THE STUDY WILL ASSESS MEASURES SUCH AS HEADACHE INTENSITY AND TIME SPENT WITH MODERATE OR SEVERE PAIN DURING TREATMENT. THIS STUDY IS ALSO BEING CONDUCTED TO OBTAIN MORE INFORMATION ON THE COMBINED EFFECT OF ERENUMAB AND TRIPTAN MEDICATION, SUCH AS THAT COMMONLY RECEIVED TO TREAT MIGRAINE ATTACKS.

Status
In recruitment

Technical Summary

  • GLOBAL EVALUATION OF THE EFFICACY OF ERENUMAB IN SUBJECTS WITH HIGH-FREQUENCY EPISODIC MIGRAINE WITH A HISTORY OF AT LEAST 1 PREVIOUS FAILURE OF PREVENTIVE TREATMENT: A GLOBAL PHASE 4, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
  • Code EudraCT: 2019-003646-33
  • Protocol number: 20190008
  • Promoter: Amgen Inc.
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.